Strong H1 2026 results driven by biosimilars and new launches led to 5% net sales growth and 15% core EBITDA increase. Guidance for 2026 is reaffirmed, with robust pipeline expansion, regulatory milestones, and major US litigation resolved, supporting confidence in future growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.